Candesartan Cilexetil, a Novel Angiotensin II Type 1 (AT1) Receptor Blocker, Reduces Microalbuminuria in Patients with Type II Diabetes Mellitus and Mild Hypertension

By TRENKWALDER P.   DAHL K.   LEHTOVIRTA M.   MULDER H.  

Blood Pressure, Vol. 9, Iss. 1, 2000-05 ,pp. : 57-57

Informa Healthcare

Access to resources Recommend Favorite

Effects of Selective Angiotensin II Type 1 Receptor Blockade with Losartan on Arterial Compliance in Patients with Mild Essential Hypertension

By KLEMSDAL TOR O.   MOAN ANDREAS   KJELDSEN SVERRE E.  

Blood Pressure, Vol. 8, Iss. 4, 1999-12 ,pp. : 214-219

Informa Healthcare

Access to resources Recommend Favorite

TRANSCEND Aftermath: Angiotensin II Type 1 Receptor Antagonists (Angiotensin Receptor Blockers) at the Clinical Crossroad

By Volpe Massimo  

High Blood Pressure & Cardiovascular Prevention, Vol. 16, Iss. 1, 2009-05 ,pp. : 1-6

Adis International

Access to resources Recommend Favorite

Administration of Angiotensin Receptor II Blockade Improves Vascular Function, Urinary Albumin Excretion, and Left Ventricular Hypertrophy in Low-Risk Essential Hypertensive Patients Receiving Antihypertensive Treatment with Calcium Channel Blockers

By Watanabe Yoshihiko  

Clinical and Experimental Hypertension, Vol. 35, Iss. 2, 2013-04 ,pp. : 87-94

Informa Healthcare

Access to resources Recommend Favorite

Beneficial Effect of Switching from a Combination of Angiotensin II Receptor Blockers other than Losartan and Thiazides to a Fixed Dose of Losartan/Hydrochlorothiazide on Uric Acid Metabolism in Hypertensive Patients

By Ohshiro Katsuhiko   Sakima Atsushi   Nakada Seigo   Kohagura Kentaro   Yamazato Masanobu   Tana Takeshi   Ohya Yusuke  

Clinical and Experimental Hypertension, Vol. 33, Iss. 8, 2011-12 ,pp. : 565-570

Informa Healthcare

Access to resources Recommend Favorite